Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 7/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889842 | 0.86 | MEN1 (0.38) | ALDH1A1KIF11MEN1KMT2ATSHR | |
| SCHEMBL889970 | 0.84 | KMT2A (0.37) | ALDH1A1LMNAKMT2A | |
| SCHEMBL23373405 | 0.78 | ASAH1 (0.43) | ALDH1A1HPGD | |
| SCHEMBL21297524 | 0.78 | ASAH1 (0.41) | ALDH1A1HPGD | |
| SCHEMBL21297523 | 0.78 | ASAH1 (0.43) | ALDH1A1HPGD | |
| SCHEMBL20650683 | 0.78 | CYP2D6 (0.42) | ALDH1A1KIF11MEN1KMT2ATDP1 | |
| SCHEMBL890354 | 0.77 | ALDH1A1 (0.46) | ALDH1A1LMNAKIF11MEN1KMT2A | |
| SCHEMBL25707541 | 0.75 | ASAH1 (0.40) | ALDH1A1 | |
| SCHEMBL13160565 | 0.72 | KIF11 (0.42) | KIF11KCNH2 | |
| SCHEMBL8842993 | 0.71 | MMP2 (0.46) | ALDH1A1KIF11MEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8465921-B2 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | ELITECH HOLDING B.V. (NL) | 2013-06-18 | — | — | US | disclosed |
| US-20110275070-A1 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | EPOCH PHARMACEUTICALS, INC. | 2011-11-10 | — | — | US | disclosed |
| US-7794945-B2 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | ELITECH HOLDING B.V. (NL) | 2010-09-14 | — | — | US | disclosed |
| US-7794945-B2 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | ELITECH HOLDING B.V. (NL) | 2010-09-14 | — | — | US | disclosed |
| US-7556923-B1 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | EPOCH BIOSCIENCES, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20090048427-A1 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | EPOCH BIOSCIENCES, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048427-A1 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | EPOCH BIOSCIENCES, INC. (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048427-A1 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | DDB1, LIG3, MSH2 | ALDH1A1 4598/4885LMNA 3853/4885KIF11 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.